<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03972150</url>
  </required_header>
  <id_info>
    <org_study_id>1336-0012</org_study_id>
    <nct_id>NCT03972150</nct_id>
  </id_info>
  <brief_title>A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer</brief_title>
  <official_title>An Open Label, Phase I Study of BI 836880 Monotherapy and Combination Therapy of BI 836880 and BI 754091 in Japanese Patients With Advanced Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is:&#xD;
&#xD;
      Part I&#xD;
&#xD;
        -  To determine Maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of BI&#xD;
           836880 monotherapy Part II&#xD;
&#xD;
        -  To determine MTD and/or RP2D of the combination therapy of BI 836880 and BI 754091&#xD;
&#xD;
      The secondary objectives are:&#xD;
&#xD;
      Part I&#xD;
&#xD;
        -  To document the safety and tolerability, and characterise pharmacokinetics (PK) of BI&#xD;
           836880 as monotherapy Part II&#xD;
&#xD;
        -  To document the safety and tolerability, and characterise PK of the combination therapy&#xD;
           of BI 836880 and BI 754091&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 12, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">October 27, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part I and II: Maximum tolerated dose (MTD)</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part I and II: Number of patients with Dose Limiting Toxicity (DLTs) in the Maximum tolerated dose (MTD) evaluation period</measure>
    <time_frame>Up to 3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part I: Cmax: maximum measured concentration of BI 836880 in plasma</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: AUC0-504h: area under the concentration-time curve of BI 836880 in plasma over the time interval from 0 to 504 hours</measure>
    <time_frame>Up to 504 hours after first, second and fourth infusion cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Cmax: maximum measured concentration of BI 836880 and BI 754091 in plasma</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: AUC0-504h: area under the concentration-time curve of BI 836880 and BI 754091 in plasma over the time interval from 0 to 504 hours</measure>
    <time_frame>Up to 504 hours after first and fourth infusion cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Part I: BI 836880 alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I followed by Part II</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II: BI 836880 and BI 754091</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 836880</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Part I: BI 836880 alone</arm_group_label>
    <arm_group_label>Part II: BI 836880 and BI 754091</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 754091</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>Part II: BI 836880 and BI 754091</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Of legal age (according to local legislation) at screening. No upper limit.&#xD;
&#xD;
          -  Signed and dated written informed consent in accordance with International Council on&#xD;
             Harmonisation (ICH) Good Clinical Practice (GCP) and local legislation prior to&#xD;
             admission to the trial.&#xD;
&#xD;
          -  Male or female patients. Women of childbearing potential (WOCBP) and men able to&#xD;
             father a child must be ready and able to use highly effective methods of birth control&#xD;
             per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used&#xD;
             consistently and correctly, starting with the screening visit and through 6 months&#xD;
             after the last dose of study treatment. A list of contraception methods meeting these&#xD;
             criteria is provided in the patient information. The requirement of contraception does&#xD;
             not apply to women of no childbearing potential and men not able to father a child,&#xD;
             but they must have an evidence of such at screening.&#xD;
&#xD;
          -  Patients with a confirmed diagnosis of advanced, unresectable, and/or metastatic solid&#xD;
             tumours (any type). Measurable lesion not mandatory for participation in this trial.&#xD;
&#xD;
          -  Patients with no therapy of proven efficacy, or who are not amenable to standard&#xD;
             therapies.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.&#xD;
&#xD;
          -  Recovery from all reversible adverse events of previous anti-cancer therapies to&#xD;
             baseline or Common Terminology Criteria for Adverse Events (CTCAE) grade 1, except for&#xD;
             alopecia (any grade), sensory peripheral neuropathy, must be ≤ CTCAE grade 2 or&#xD;
             considered not clinically significant.&#xD;
&#xD;
          -  Adequate organ function.&#xD;
&#xD;
          -  Further inclusion criteria apply.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Known hypersensitivity to the trial drugs or their excipients or risk of allergic of&#xD;
             anaphylactic reaction to drug product according to Investigator judgement (e.g.&#xD;
             patient with history of anaphylactic reaction or autoimmune disease that is not&#xD;
             controlled by nonsteroidal anti-inflammatory drugs (NSAIDs), inhaled corticosteroids,&#xD;
             or the equivalent of ≤10 mg/day prednisone).&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) infection. Test results obtained&#xD;
             in routine diagnostics are acceptable if done within 14 days before the informed&#xD;
             consent date.&#xD;
&#xD;
          -  Any of the following laboratory evidence of hepatitis virus infection.&#xD;
&#xD;
               -  Positive results of hepatitis B surface (HBs) antigen&#xD;
&#xD;
               -  Presence of hepatitis B core (HBc) antibody together with hepatitis virus B (HBV)&#xD;
                  Deoxyribonucleic acid (DNA)&#xD;
&#xD;
               -  Presence of hepatitis virus C (HCV) Ribonucleic acid (RNA) Test results obtained&#xD;
                  in routine diagnostics are acceptable if done within 14 days before the informed&#xD;
                  consent date.&#xD;
&#xD;
          -  History of severe known hypersensitivity reactions to other mAbs.&#xD;
&#xD;
          -  Immunosuppressive corticosteroid doses (&gt;10 mg prednisone daily or equivalent) within&#xD;
             4 weeks prior to the first dose of trial medication.&#xD;
&#xD;
          -  Any investigational or anti-tumour treatment within 4 weeks or 5 half-life periods&#xD;
             (whichever is shorter) prior to the initiation of trial treatment.&#xD;
&#xD;
          -  Serious concomitant disease, especially those affecting compliance with trial&#xD;
             requirements or which are considered relevant for the evaluation of the endpoints of&#xD;
             the trial drug, such as neurologic, psychiatric, infectious disease or active ulcers&#xD;
             (gastrointestinal tract, skin) or laboratory abnormality that may increase the risk&#xD;
             associated with trial participation or trial drug administration, and in the judgment&#xD;
             of the investigator would make the patient inappropriate for entry into the trial.&#xD;
&#xD;
          -  Major injuries and/or surgery or bone fracture within 4 weeks of start of treatment,&#xD;
             or planned surgical procedures during the trial period.&#xD;
&#xD;
          -  Patients with personal or family history of QT prolongation and/or long QT syndrome,&#xD;
             or prolonged QTcF (Corrected QT interval by Fridericia) at screening (&gt;470 ms).&#xD;
&#xD;
          -  Significant cardiovascular/cerebrovascular diseases (i.e. uncontrolled hypertension,&#xD;
             unstable angina, history of infarction within past 6 months, congestive heart failure&#xD;
             &gt;NYHA [New York Heart Association] class II).&#xD;
&#xD;
        Uncontrolled hypertension is defined as follows: Blood pressure in rested and relaxed&#xD;
        condition ≥140 mmHg, systolic or ≥90 mmHg diastolic (with or without medication)&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction (LVEF) &lt;50% measured locally by echocardiography&#xD;
&#xD;
          -  History of severe haemorrhagic or thromboembolic event in the past 12 months&#xD;
             (excluding central venous catheter thrombosis and peripheral deep vein thrombosis).&#xD;
&#xD;
          -  Known inherited predisposition to bleeding or to thrombosis in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
          -  Untreated brain metastasis(es) that may be considered active. Patients with previously&#xD;
             treated brain metastases may participate provided they are stable (i.e., without&#xD;
             evidence of progressive disease (PD) by imaging for at least 4 weeks prior to the&#xD;
             first dose of trial treatment, and any neurologic symptoms have returned to baseline),&#xD;
             and there is no evidence of new or enlarging brain metastases&#xD;
&#xD;
          -  Patients who require full-dose anticoagulation (according to local guidelines). No&#xD;
             Vitamin K antagonist and other anticoagulation allowed; Low Molecular Weight Heparin&#xD;
             (LMWH) allowed only for prevention not for curative treatment.&#xD;
&#xD;
          -  History (including current) of interstitial lung disease or pneumonitis within the&#xD;
             last 5 years.&#xD;
&#xD;
          -  Patients who must or wish to continue the intake of restricted medications or any drug&#xD;
             considered likely to interfere with the safe conduct of the trial&#xD;
&#xD;
          -  Patients not expected to comply with the protocol requirements or not expected to&#xD;
             complete the trial as scheduled. (e.g. chronic alcohol or drug abuse or any other&#xD;
             condition that, in the investigator's opinion, makes the patient an unreliable trial&#xD;
             participant).&#xD;
&#xD;
          -  Patients who were previously treated in this trial.&#xD;
&#xD;
          -  Patients with haematological malignancies.&#xD;
&#xD;
          -  Women who are pregnant, nursing, or who plan to become pregnant.&#xD;
&#xD;
          -  Further exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Shizuoka, Sunto-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

